MEDICAL DEVICES

MedTech Company STENTiT Raises €1.8 million in Seed Round

STENTiT | April 25, 2022

MedTech Company

STENTiT, a medical device company bringing a novel class of regenerative endovascular implants for the treatment of cardiovascular diseases, has closed a €1.8 million seed investment round. The funding facilitates further pre-clinical development and batch production of a regenerative stent (see video) for peripheral indications. The investment was made by Dutch investors NextGen Ventures, Brabant Development Agency and the Ten Cate Investment Company.

STENTiT is an emerging player in the field of regenerative medical devices, offering a breakthrough solution for cardiovascular interventions by developing first-of-its-kind endovascular implants with regenerative capacity. Using a catheter-based approach, these devices provide the ability to restore arteries without the need for an invasive surgical intervention. The aim is to ultimately restore the affected blood vessel from the inside out to provide a lifelong solution.

As a first target indication, the company wants to improve the treatment of critical limb ischemia. This progressive form of peripheral artery disease affects almost 5 million people in the EU and the US in which the blood flow to the foot is severely being compromised. Unfortunately, current treatment options are ineffective, resulting in amputation within 6 months in 40% of these patients.

With the regenerative stent, blood flow to the foot will be maintained by securing vascular patency using temporary mechanical support and improving long-term efficacy by inducing vascular repair, thereby preventing thousands of amputations each year.

"We are excited to receive the support of these esteemed Dutch early-stage investors. This financing round validates our vision to bring a novel class of implants that can rebuild the affected blood vessels. We are looking forward taking the next steps getting our regenerative stents ready for clinical trials. With our first product, we aim to treat millions of patients suffering from peripheral artery diseases, and save their limbs from amputation."

Bart Sanders, CEO of STENTiT

 

About STENTiT

STENTiT is a medical device spin-off company from the Dutch Eindhoven University of Technology, focusing on the development of regenerative endovascular implants. These bioresorbable devices trigger a natural healing response by the circulating blood cells, in which the implant is being replaced by new vascular tissue to restore the artery from the inside-out.

Since the establishment of the company, STENTiT has received broad international recognition and awards for its high-potential approach, covering world leading stages. As the company is currently going through the next translational phases, STENTiT is on its way to fulfill its ambition to become the new standard in endovascular treatment, providing a life-changing solution for millions of cardiovascular patients around the world.

Spotlight

Most health systems plan to expand in 2018, with physician offices and hospitals being the leading targets for acquisition. Many organizations are seeking to align supply chain between their new and existing care facilities to reduce costs, but find alignment challenging as supply needs can be very different across the continuum of care, according to a new infographic by Health Industry Distributors Association. The infographic examines the healthcare merger and acquisition market, as well as the supply chain impacts.

Spotlight

Most health systems plan to expand in 2018, with physician offices and hospitals being the leading targets for acquisition. Many organizations are seeking to align supply chain between their new and existing care facilities to reduce costs, but find alignment challenging as supply needs can be very different across the continuum of care, according to a new infographic by Health Industry Distributors Association. The infographic examines the healthcare merger and acquisition market, as well as the supply chain impacts.

Related News

FUTURE OF HEALTHCARE

Alight Announces Network Agreement With Children’s Hospital Colorado

Alight Solutions and Children’s Hospital Colorado | September 09, 2022

Alight, Inc. a leading cloud-based human capital technology and services provider announced an institutional agreement with Children’s Hospital Colorado one of the nation’s premier pediatric healthcare systems, to join Alight’s Expert Physician Network. This collaboration further expands Alight’s ability to provide employees and their loved ones guidance from the nation’s leading specialists when facing a new or complex diagnosis. Through the agreement, families will now have access to the Children’s Colorado world-class network of physicians when seeking an expert opinion from Alight, providing the opportunity to drive more informed health decisions before, during and after treatment, as well as improved patient outcomes and lower costs for users. “We are delighted to join forces with Children’s Colorado’s network of physicians, further demonstrating Alight’s leadership in healthcare navigation. Our expanding work among the nation’s preeminent hospitals accentuates our commitment to delivering the people we serve with the best guidance and technology possible, especially in this instance when children are directly impacted.” Bipin Mistry, Chief Medical Officer at Alight The Expert Physician Network is made up of over 2,000 of the nation’s top physicians. Using Alight’s award-winning platform for virtual expert opinions, these specialists collaborate with Alight’s team to respond to participant questions, provide guidance on diagnoses and treatment options they have received from their provider, and work together with other leading specialists to deliver multidisciplinary opinions when needed. “By providing this service, we can provide more children the comprehensive, world-class expertise offered by Children’s Colorado, while keeping them close to home,” said Raphe Schwartz, Chief Strategy Officer at Children’s Hospital Colorado. “With this collaboration, we are thrilled to be able to support children and families nationwide by providing them with high-quality, family-centered guidance when they need an expert opinion.” About Alight Solutions Alight is a leading cloud-based human capital technology and services provider that powers confident health, wealth and wellbeing decisions for 36 million people and dependents. Our Alight Worklife® platform combines data and analytics with a simple, seamless user experience. Supported by our global delivery capabilities, Alight Worklife is transforming the employee experience for people around the world. With personalized, data-driven health, wealth, pay and wellbeing insights, Alight brings people the security of better outcomes and peace of mind throughout life’s big moments and most important decisions. About Children’s Hospital Colorado Children’s Hospital Colorado is one of the nation’s leading and most expansive nonprofit pediatric healthcare systems with a mission to improve the health of children through patient care, education, research and advocacy. Founded in 1908 and recognized as a top 10 children’s hospital by U.S. News & World Report, Children’s Colorado has established itself as a pioneer in the discovery of innovative and groundbreaking treatments that are shaping the future of pediatric healthcare worldwide. Children’s Colorado offers a full spectrum of family-centered care at its urgent, emergency and specialty care locations throughout Colorado, including an academic medical center on the Anschutz Medical Campus in Aurora, hospitals in Colorado Springs, Highlands Ranch and Broomfield, and outreach clinics across the region.

Read More

HEALTHTECH SECURITY

KORU Medical Systems Appoints Brent Rutland as Vice President of Medical Affairs

KORU Medical | October 13, 2022

KORU Medical Systems, Inc. a leading medical technology company focused on the development of innovative and easy-to-use subcutaneous infusion solutions announced the appointment of Brent Rutland as the Company’s new Vice President of Medical Affairs. Mr. Rutland will provide leadership in the Company’s clinical and data generation strategies, key opinion leader engagement, assessing new subcutaneous drug candidates for use with the Company’s products and overseeing the medical affairs team. Additionally, Mr. Rutland will be the clinical resource for the Company’s efforts in regulatory submissions, failure modes and effects analysis, health hazard evaluations, human factors design, new product development and clinical evaluation updates. “We are excited to bring Brent’s competence to the organization – his background was a perfect fit. His expertise will advance clinical evidence generation in support of our product pipeline, provide valuable insight to our drug therapy candidates and help develop important key opinion leader relationships. Brent has helped build multiple data and clinical strategies, internal teams, and external networks in his past. His deep industry experience and passion for the patient, will make him an impactful contributor to the Company’s strategy.” Linda Tharby, President and CEO Mr. Rutland’s career history spans an impressive 27 years and includes working with Baxter Healthcare as a Senior Medical Science Liaison and most recently with La Jolla Pharmaceutical Company as a Senior Director, Health Outcomes. During his career he helped launch 7 vaccines, 4 drugs and 1 device. Most notably, Brent aided Baxter in the launch of Hylenex for SQ rehydration where he also helped build the Medical Affairs department. He has received several awards throughout his career, with the most recent being the President’s Circle Award for Medical Affairs at La Jolla. Brent holds a Bachelor of Science degree from Texas A&M University, an MBA in Global Management from the University of Houston, and his Master of Public Health from the University of North Carolina in Epidemiology. “I was immediately drawn to the opportunity to work at KORU Medical as I saw the potential for future growth supported by building out the medical science and the team,” said Brent Rutland, Vice President of Medical Affairs. “Medical affairs helps fulfill the unmet needs of the patient through the generation and delivery of scientific evidence to various key outside stakeholders. I look forward to developing a collaborative strategy to support the Company’s overall goals.” About KORU Medical KORU Medical develops, manufactures, and commercializes innovative and easy-to-use subcutaneous infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System. currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in the home and alternate care settings.

Read More

HEALTH TECHNOLOGY

Stryker Launches Q Guidance System with Spine Guidance Software

Stryker | September 28, 2022

Stryker one of the world’s leading medical technology companies, announced the launch of its Q Guidance System for spine applications. The System combines new optical tracking options provided by a redesigned, state-of-the-art camera with sophisticated algorithms of the newly launched Spine Guidance Software to deliver more surgical planning and navigation capability than ever before. When used with the Q Guidance System, the Spine Guidance Software is intended as a planning and intraoperative guidance system to enable open or percutaneous computer-assisted surgery and is the first spine navigation software to receive FDA clearance for use with pediatric patients aged 13 and older. “The Q Guidance System offers cutting-edge tracking options with its 4th generation FP8000 camera, and Spine Guidance Software allows for advanced planning and computer-assisted execution. With the addition of the Q Guidance System, customers now have access to a robust solution that includes imaging, guidance, and instruments and is fully integrated and designed to meet complex customer needs. In the years to come, our goal is to use the versatility of this System to help advance our technologies across multiple specialties including cranial, spine, ENT, and orthopaedics.” Robbie Robinson, President of the Spine division Q Guidance offers surgeons numerous benefits, including A proprietary camera: The Q Guidance System features a 4th generation FP8000 camera that offers unmatched speeds and the flexibility of multiple optical tracking methods, including full-spectrum active/passive hybrid optical tracking.1 It is the only guidance system with proprietary active technology and a non-invasive patient tracker, SpineMask. Image processing: Spine Guidance Software features completely redesigned applications, semi-automatic and automatic processing features, gesture recognition, and broad compatibility with various types of image sets. Spine Guidance Software: Spine Guidance Software is designed to help surgeons optimize their workflow, minimize their time in the OR and address complex clinical decisions and techniques intraoperatively. Its computational power is designed to support our spine product and software roadmap. It is our intention to develop and release new technologies within the Q ecosystem. “In my experience, Spine Guidance Software truly simplifies preoperative planning, navigation and execution,” said Stephen George, M.D., Director of Spine Surgery, Nicklaus Children's Hospital. “From what I have seen, the Q Guidance System is a powerful platform that has provided reliability and performance in a solution that is conveniently scalable to a wide array of surgical procedures, ranging from a single level fusion to a multi-level deformity correction. When used with the Airo TruCT scanner, Spine Guidance Software is designed to minimize time spent intraoperatively planning, thanks to its auto segmentation capability, while also allowing us the benefit of being able to image the patient in the surgical position. Its intuitive and customizable software enables us to configure the System to fit our preferences.” Stryker will be featuring the Q Guidance System and offering demonstrations at several upcoming meetings, including Society for Minimally Invasive Spine Surgery (SMISS) 2022 Annual Forum in Las Vegas, Sept. 29–Oct. 1, 2022 Congress of Neurological Surgeons (CNS) 2022 Annual Meeting in San Francisco, Oct. 8–12, 2022 North American Spine Society (NASS) Annual Meeting in Chicago, Oct. 12–15, 2022 About Stryker Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Medical and Surgical, Neurotechnology, and Orthopaedics and Spine that help improve patient and hospital outcomes. Alongside its customers around the world, Stryker impacts more than 100 million patients annually.

Read More